Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC) Meeting Abstract
| Authors: | Venerito, M.; Kelley, R. K.; Ryoo, B. Y.; Merle, P.; Park, J. W.; Bolondi, L.; Chan, S. L.; Lim, H. Y.; Baron, A.; Parnis, F.; Knox, J.; Cattan, S.; Yau, T.; Lougheed, J. C.; Milwee, S.; El-Khoueiry, A. B.; Cheng, A. L.; Meyer, T.; Abou-Alfa, G. K. |
| Abstract Title: | Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC) |
| Meeting Title: | Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 41 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2018 Sep 28-Oct 2 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2018-09-01 |
| Start Page: | 282 |
| End Page: | 283 |
| Language: | English |
| ACCESSION: | WOS:000446816500687 |
| PROVIDER: | wos |
| PUBMED: | 30261496 |
| DOI: | 10.1159/000492737 |
| Notes: | Meeting Abstract: P878 -- Source: Wos |
